Evidence map›Paper›PMID 38338310›Full record

ArticleMolecules (Basel, Switzerland)2024

A High-Throughput NMR Method for Lipoprotein-X Quantification.

Erwin Garcia, Irina Shalaurova, Steven P Matyus, Lita A Freeman, Edward B Neufeld, Maureen L Sampson, Rafael Zubirán, Anna Wolska, Alan T Remaley, James D Otvos and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.9field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Erwin GarciaLabcorp, Morrisville, NC 27560, USA.
Irina ShalaurovaLabcorp, Morrisville, NC 27560, USA.
Steven P MatyusLabcorp, Morrisville, NC 27560, USA.
Lita A FreemanTranslational Vascular Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Edward B NeufeldTranslational Vascular Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Maureen L SampsonClinical Center, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0003-0885-250X
Rafael ZubiránTranslational Vascular Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0003-4274-3585
Anna WolskaTranslational Vascular Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0001-9479-0741
Alan T RemaleyTranslational Vascular Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA.
James D OtvosTranslational Vascular Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Margery A ConnellyLabcorp, Morrisville, NC 27560, USA.ORCID 0000-0002-3917-592X
National Institutes of Health · USLabCorp (United States) · USNational Institutes of Health Clinical Center · US

Funding

Development and assessment of cardiovascular risk biomarkersZIAHL006275 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI REMALEY, ALAN THOMAS · 2022 to 2025
$6.0M
NIH HHS CRADA research grant
6 · The paper itself

Abstract

Lipoprotein X (LP-X) is an abnormal cholesterol-rich lipoprotein particle that accumulates in patients with cholestatic liver disease and familial lecithin-cholesterol acyltransferase deficiency (FLD). Because there are no high-throughput diagnostic tests for its detection, a proton nuclear magnetic resonance (NMR) spectroscopy-based method was developed for use on a clinical NMR analyzer commonly used for the quantification of lipoproteins and other cardiovascular biomarkers. The LP-X assay was linear from 89 to 1615 mg/dL (cholesterol units) and had a functional sensitivity of 44 mg/dL. The intra-assay coefficient of variation (CV) varied between 1.8 and 11.8%, depending on the value of LP-X, whereas the inter-assay CV varied between 1.5 and 15.4%. The assay showed no interference with bilirubin levels up to 317 mg/dL and was also unaffected by hemolysis for hemoglobin values up to 216 mg/dL. Samples were stable when stored for up to 6 days at 4 °C but were not stable when frozen. In a large general population cohort (

Indexed as

CholestasisLiver DiseasesCholesterolHumansLipoprotein-XMagnetic Resonance SpectroscopyCholesterolLipoprotein-XcholestasishypercholesterolemiaLCAT deficiencylipoprotein-X

Identifiers

PMID38338310
PMCPMC10856374
OpenAlexW4391173607

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.